iCare HOME2 Clinical Trial

Glaucoma Clinical Trial

Official title:

iCare HOME2 Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05162989
• Other study ID #: TA023-207
• Status: Completed
• Phase: N/A
• Start date: November 26, 2021
• Est. completion date: December 15, 2021

Study information

• Verified date: December 2021
• Source: Icare Finland Oy
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this clinical study is to provide information about the variability of the intraocular pressure (IOP) self-measurements with the iCare HOME2 tonometer in comparison to the variability of the IOP measurements with the reference tonometer (iCare IC200), over a wide range of IOP values.

Description:

The clinical study is planned to estimate the variability of the IOP measurement of iCare HOME2 and IC200. In the study, the subjects will learn to operate the iCare HOME2 tonometer independently by using the labeling materials provided to them. Once they learn to operate the tonometer, subjects will take three self-measurements on the selected eye both in sitting and supine position. The variability of the measurement results taken with iCare HOME2 will be compared to the variability of the measurement results taken with iCare IC200 by using the recorded results from the study subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 47
• Est. completion date: December 15, 2021
• Est. primary completion date: December 15, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Glaucoma patients having confirmed optic nerve damage with visual field defects consistent with the glaucomatous optic neuropathy or
• Glaucoma-suspects being followed because of elevated IOP, and/or because of other risk factors for developing glaucoma or optic nerve damage.

Exclusion Criteria:

• Active ocular infection (e.g., pink eye or infectious conjunctivitis)
• Recent trauma to the eye including corneal laceration or corneal/scleral perforation
• Disabling arthritis or difficulty handling the tonometer
• Severe difficulty in opening the eyes including abnormal contractions or twitches of the eyelid (blepharospasm)
• Involuntary, rapid, and repetitive eye movements (nystagmus)
• Low uncorrected near visual acuity of 20/200 or below
• Significant glaucomatous central field loss
• Only one functional eye
• Poor or off-center visual fixation
• Poor hearing and/or communicates using sign language
• Keratoconus (or other corneal disorder)
• Congenitally small eye (microphthalmos)
• Enlarged eyeball from the childhood glaucoma (buphthalmos)
• Previous experience using or interacting with the HOME tonometer during usability tests or clinical trials
• Any affiliation with Icare and its employees
• High corneal astigmatism (>3d)
• History of prior invasive corneal surgery including corneal laser surgery less than six months ago (e.g., LASIK, LASEK, Smile)
• Corneal scarring
• Very thick or very thin corneas (central corneal thickness greater than 600 µm or less than 500 µm)
• Cataract extraction within the last 2 months
• Wearing contact lenses during the study

Related Conditions & MeSH terms

• Glaucoma
• Intraocular Pressure

Intervention

Device:
• iCare HOME2 vs iCare IC200
Measurement of IOP with iCare HOME2 compared with iCare IC200.

Locations

Country	Name	City	State
United States	East West Eye Institute	Los Angeles	California

Sponsors (1)

Lead Sponsor	Collaborator
Icare Finland Oy

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Repeatability of IOP measurements	Repeatability of IOP measurements comparison of iCare HOME2 vs iCare IC200	Through study completion, an average of 1-2 months